Navigation Links
How the Parkin enzyme inhibits neuronal cell death
Date:12/18/2013

Cell biologists at the Ruhr-Universitt Bochum (RUB) have launched a new project to unravel the role of the enzyme Parkin in promoting neuronal survival. The team of Prof Dr Konstanze F. Winklhofer from the Institute of Physiological Chemistry, Department of Molecular Cell Biology, is looking for new therapeutic options to treat Parkinson's disease. The Michael J. Fox Foundation finances this research project with 125,000 US Dollars.

Parkin activates a signal pathway that protects neurons

Parkinson's disease is characterized by the degeneration of neurons that produce the neurotransmitter dopamine. In some cases, mutations in the Parkin gene are the underlying cause of this disease. The RUB researchers have recently discovered that Parkin regulates a signal pathway that protects neurons under cellular stress from damage. When the integrity of mitochondria, the cell's powerhouses, is impaired, Parkin is recruited to a protein complex called LUBAC (linear ubiquitin chain assembly complex) and increases its activity. A signal pathway is then activated that leads to the increased expression of protective factors, thus preventing cell death. The RUB team investigates the molecular mechanism of how parkin activates LUBAC and which other regulators play a role in this process. The goal of the project is to identify novel targets to halt or delay the neurodegenerative process in Parkinson's disease.


'/>"/>
Contact: Dr. Konstanze Winklhofer
konstanze.winklhofer@rub.de
49-234-322-2428
Ruhr-University Bochum
Source:Eurekalert

Page: 1

Related biology news :

1. Investigating the link between Parkinsons and pesticides
2. Genetic mutation increases risk of Parkinsons disease from pesticides
3. Gene-silencing study finds new targets for Parkinsons disease
4. UCLA, Emory researchers find a chemical signature for fast form of Parkinsons
5. Why psychosis is frequently associated with Parkinsons disease?
6. Lasers might be the cure for brain diseases such as Alzheimers and Parkinsons
7. Absence of the SMG1 protein could contribute to Parkinsons and other neurological disorders
8. Rare childhood disease may hold clues to treating Alzheimers and Parkinsons
9. PD map: Putting together the pieces of the Parkinsons puzzle
10. Garvan Institute receives grant to research role of long non-coding RNAs in Parkinsons disease
11. Mild cognitive impairment in Parkinsons disease may be linked with extensive neurodegeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , ... Well Made Simple," and 23andMe , the leading ... better food choices.  Zipongo can now provide customers with ... preferences, health goals and biometrics, but also genetic markers ... choices. Zipongo,s personalized food decision support platform ...
(Date:3/2/2017)... Summary This report provides all the information you ... activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ...
(Date:3/1/2017)... 1, 2017  Aware, Inc. (NASDAQ: AWRE), a leading ... Richard P. Moberg has resigned, effective March 3, ... Financial Officer and Treasurer of Aware citing a desire ... a member of the Board of Directors of Aware. ... Executive Officer and co-President, General Counsel has been named ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... On Thursday, March 23, 2017, ... down 0.07%; the Dow Jones Industrial Average edged 0.02% ... closed at 2,345.96, marginally dropping 0.11%. US markets saw ... 4 sectors finished in red, and 1 sector ended ... reports coverage on the following Biotechnology equities: BioDelivery Sciences ...
(Date:3/23/2017)... Malden, MA (PRWEB) , ... March 23, 2017 ... ... as, “a viscoelastic material that exhibits both viscous and elastic characteristics when deformed, ... AxioMed disc polymer exhibits properties to gently absorb compressive forces and return to ...
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
(Date:3/23/2017)... 23, 2017  BioPharmX Corporation (NYSE MKT: BPMX), ... dermatology market, today reported financial results for the ... will provide an update on the company,s clinical ... "We are pleased to report that last ... said President Anja Krammer. "We achieved key clinical ...
Breaking Biology Technology: